Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

256results about How to "Non-allergenic" patented technology

Color-protecting and fresh-keeping method for fresh-cut potatoes

The invention discloses a color-protecting and fresh-keeping method for fresh-cut potatoes. The method includes selecting fresh or stored potatoes as the raw material, washing cleanly, peeling, cutting into chips with thicknesses of 0.5-1.0mm, adding a composite color-protecting fresh-keeping solution having the same mass with the potato chips, and soaking for 10-30min at 20 DEG C-30 DEG C; then fishing out the potato chips from the composite color-protecting fresh-keeping solution, washing cleanly with water, soaking in water at 10-150w ultrasonic power and 10-50kHz ultrasonic frequency for 10-30min of ultrasonic time; fishing out the potato chips and draining off, processing for 10-30min under the condition of subzero 0.01MPa-subzero 0.09MPa of vacuum degree; and finally taking the potato chips out of the vacuum environment and soaking immediately into an arbutin solution with the concentration of 0.05-0.3mmol/L, soaking for 5-15min, taking the soaked potato chips out and draining for 1-3min, performing decompression packaging immediately, and storing at an environment of subzero 4 DEG C to zero DEGC. The method adopts ultrasonic and vacuum cooperative processing as well as the Chinese herb extract arbutin as the color-protecting fresh-keeping agent to inhibit enzyme and microbial activities, is better in effect compared with the prior art, and ensures that various potato processed products are prevented from brown stain in a cold storage process for more than 10 days.
Owner:SHANXI AGRI UNIV

Artemisinin derivatives freeze-dried preparation and preparation method

The present invention relates to a frozen dry preparation of drug artemisinin derivatives and the preparation method. The present invention is composed of artemisinin derivatives and water-soluble cyclodextrin derivatives, the weight ratio of the artemisinin derivatives and water-soluble cyclodextrin derivatives is 1: 30 to 70, the smashed artemisinin derivatives are added into the water solution of the water-soluble cyclodextrin derivatives at 50 DEG C to 90 DEG C for agitating and dissolving, then the frozen dry preparation is prepared by the conventional process of the injection and the frozen drying. The low-temperature micro-powder technology of the present invention has the advantages that the technology can ensure the physical and chemical properties of the artemisinin derivatives to be consistent before and after the smashing, the process is relatively simple compared with the prior art, the equipments make use of the existing production equipments of the company, thus saving the investment and shorten the production cycle; the dispensing solvent is the water for injection, without the organic solvents, surfactants and cosolvents, so as to improve the safety; the present invention is easy to be dissolved in water, and has fast dissolution speed and the infinite dilution stability, thus avoiding the secondary pollution caused in the other methods which firstly prepare the artemisinin derivatives into the inclusions by using the organic solvents and then sub-package the inclusions thereof.
Owner:KPC PHARM INC

Levocarnitine for injection and preparation method thereof

The invention discloses a levocarnitine for injection and a preparation method thereof. The preparation method comprises the following steps: weighing sodium dihydrogen phosphate and sodium hydroxide, using injection water to dissolve the weighed sodium dihydrogen phosphate and sodium hydroxide and diluting and uniformly mixing, dissolving levocarnitine and mannitol in the buffer solution, addingneedle active carbon and stirring uniformly, stirring for adsorption, and using filtering membrane for filtering and removing carbon; carrying out fine filtration through 0.22 mum microporous membrane, after the intermediate passed the inspection, filling the filtrate with the amount of 5 ml in 15 ml penicillin bottle (using up the liquor in 6 h after degerming), and carrying out half-plug pressing, freeze-drying, capping, visual inspection, labeling, and packaging. According to the invention, buffer salts (the buffer salt ion pair consisting of sodium dihydrogen phosphate and sodium hydroxide) with buffer effect are used in stead of traditional hydrochloric acid to regulate the pH value of the levocarnitine solution, so that the main drug is always in a stable pH environment in the wholepreparation process, and the API degradation caused by violent change of pH value of levocarnitine is avoided. Compared with the similar kind products, the levocarnitine disclosed in the invention has higher effectiveness and higher safety.
Owner:长春海悦药业股份有限公司

Medical cold-compressing plaster and preparation method thereof

The invention provides a medical cold-compressing paster which comprises a back lining layer, a gel layer and a covering layer. The gel layer is prepared from raw materials, the raw materials include,by mass, 2%-15% of a polymer substance, 2%-10% of an epidermal growth factor, 2%-8% of ceramide, 3%-8% of a moisturizer, 3%-10% of a radix bupleuri extract, 2%-8% of a dandelion extract, 3%-12% of agolden cypress extract, 5%-10% of an aloe extract, 2%-10% of a honeysuckle flower extract and the balance purified water. The invention also provides a preparation method of the medical cold-compressing paster. The medical cold-compressing paster has the advantages that the medical cold-compressing paster is convenient to use; the medical cold-compressing paster achieves both cold-compressing cooling and pain relieving, also promotes organization healing; the biocompatibility is good, and the medical cold-compressing paster does not have sensitization and irritation; the drug release performance is good, and the application time is long; the medical cold-compressing paster provides different shapes, and the different demands are met; the preparation method is easy to operate, the raw materials are wide in source, the preparation cost is low, no toxic-side effect is produced, and the medical cold-compressing paster is safe and reliable.
Owner:SHANDONG ZHUSHI PHARMA GRP CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products